# TERN (Terns Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Terns Pharmaceuticals, Inc. reported $1.03B in total assets and a net loss of $96.21M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/TERN
- Markdown: https://convexityos.com/fundamentals/TERN.md
- SEC CIK: 0001831363
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:14 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001831363&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$110.1M | Operating profit |
| Net Income | FY 2025 | -$96.21M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.03 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$82.18M | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $1.02B | Total debt: $919K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | $0 | $1.00M | $0 |
| Research & Development | $77.89M | $70.11M | $63.50M | $39.62M | $31.31M | $28.03M |
| **Operating Income** | -$110.1M | -$101.9M | -$102.6M | -$62.03M | -$49.86M | -$37.02M |
| **EBITDA** | -$110.0M | -$101.6M | -$102.3M | -$61.55M | -$49.35M | -$36.63M |
| Income Before Tax | -$95.63M | -$88.59M | -$89.97M | -$59.99M | -$49.65M | -$39.76M |
| Income Tax Expense | $581K | $260K | $239K | $358K | $508K | $813K |
| **Net Income** | -$96.21M | -$88.85M | -$90.21M | -$60.34M | -$50.16M | -$40.05M |
| Basic EPS | -$1.03 | -$1.12 | -$1.27 | -$1.67 | -$2.21 | -$102.93 |
| **Diluted EPS** | -$1.03 | -$1.12 | -$1.27 | -$1.67 | -$2.21 | -$102.93 |
| Basic Shares Outstanding | 93.2M | 79.5M | 71.3M | 36.0M | 22.7M | 285.2K |
| Diluted Shares Outstanding | 93.2M | 79.5M | 71.3M | 36.0M | 22.7M | 285.2K |

### Income Statement (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $18.90M | $19.92M | $20.35M | $18.72M | $18.00M | $15.17M | $18.35M | $18.59M |
| **Operating Income** | -$27.60M | -$27.72M | -$27.38M | -$27.43M | -$25.95M | -$24.94M | -$25.54M | -$25.45M |
| **EBITDA** | -$27.59M | -$27.70M | -$27.37M | -$27.37M | -$25.88M | -$24.86M | -$25.45M | -$25.36M |
| Income Before Tax | -$23.19M | -$24.59M | -$24.03M | -$23.82M | -$21.76M | -$21.88M | -$22.68M | -$22.28M |
| Income Tax Expense | $383K | $46K | $64K | $88K | $40K | $62K | $61K | $97K |
| **Net Income** | -$23.57M | -$24.64M | -$24.09M | -$23.91M | -$21.80M | -$21.95M | -$22.74M | -$22.37M |
| Basic EPS | -- | -$0.27 | -$0.26 | -$0.26 | -- | -$0.28 | -$0.31 | -$0.30 |
| **Diluted EPS** | -- | -$0.27 | -$0.26 | -$0.26 | -- | -$0.28 | -$0.31 | -$0.30 |
| Basic Shares Outstanding | -- | 91.7M | 91.6M | 91.5M | -- | 77.8M | 74.5M | 74.4M |
| Diluted Shares Outstanding | -- | 91.7M | 91.6M | 91.5M | -- | 77.8M | 74.5M | 74.4M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $524.7M | $161.4M | $79.93M | $143.2M | $47.70M | $74.85M |
| Short-Term Investments | $494.2M | $196.7M | $183.5M | $139.9M | $118.3M | $0 |
| **Cash & Short-Term Investments** | $1.02B | $358.2M | $263.4M | $283.1M | $166.0M | $74.85M |
| **Total Current Assets** | $1.02B | $362.1M | $267.4M | $285.2M | $166.9M | $90.87M |
| Property, Plant & Equipment, Net | $47K | $222K | $506K | $757K | $1.05M | $1.18M |
| Other Non-Current Assets | $0 | $350K | $56K | $37K | $94K | $246K |
| **Total Non-Current Assets** | $884K | $1.82M | $1.08M | $1.84M | $1.14M | $1.42M |
| **Total Assets** | $1.03B | $363.9M | $268.5M | $287.0M | $168.1M | $92.29M |
| Accounts Payable | $1.72M | $2.15M | $2.52M | $1.65M | $2.13M | $935K |
| **Total Current Liabilities** | $16.41M | $15.65M | $11.94M | $8.47M | $6.82M | $22.82M |
| Long-Term Debt | -- | -- | $0 | $544K | -- | -- |
| **Total Non-Current Liabilities** | $2.14M | $2.41M | $1.21M | $1.61M | $947K | $877K |
| **Total Liabilities** | $18.55M | $18.06M | $13.15M | $10.08M | $7.77M | $23.70M |
| **Total Debt (incl. Leases)** | $919K | $1.35M | $603K | $1.75M | -- | -- |
| Common Stock | $11K | $9.0K | $6.0K | $5.0K | $3.0K | $0 |
| Retained Earnings | -$517.7M | -$421.5M | -$332.6M | -$242.4M | -$182.1M | -$131.9M |
| Accumulated Other Comp. Income | $260K | -$279K | -$19K | -$822K | -$338K | -$124K |
| **Total Stockholders' Equity** | $1.01B | $345.9M | $255.4M | $276.9M | $160.3M | -$117.4M |
| Total Equity | $1.01B | $345.9M | $255.4M | $276.9M | $160.3M | -$117.4M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $524.7M | $150.7M | $146.0M | $139.0M | $161.4M | $270.1M | $91.50M | $65.10M |
| Short-Term Investments | $494.2M | $144.9M | $169.5M | $195.2M | $196.7M | $102.6M | $133.8M | $175.6M |
| **Cash & Short-Term Investments** | $1.02B | $295.6M | $315.4M | $334.3M | $358.2M | $372.8M | $225.3M | $240.7M |
| **Total Current Assets** | $1.02B | $300.3M | $319.0M | $337.7M | $362.1M | $376.5M | $230.2M | $245.9M |
| Property, Plant & Equipment, Net | $47K | $59K | $70K | $82K | $222K | $295K | $370K | $447K |
| Other Non-Current Assets | $0 | $359K | $356K | $351K | $350K | $56K | $55K | $55K |
| **Total Non-Current Assets** | $884K | $1.36M | $1.46M | $1.57M | $1.82M | $1.73M | $642K | $871K |
| **Total Assets** | $1.03B | $301.7M | $320.4M | $339.3M | $363.9M | $378.2M | $230.9M | $246.8M |
| Accounts Payable | $1.72M | $2.95M | $2.85M | $2.78M | $2.15M | $1.79M | $1.87M | $1.70M |
| **Total Current Liabilities** | $16.41M | $15.39M | $12.91M | $10.94M | $15.65M | $11.41M | $10.96M | $8.83M |
| Long-Term Debt | -- | -- | -- | -- | -- | $1.03M | $0 | $0 |
| **Total Non-Current Liabilities** | $2.14M | $2.20M | $2.27M | $2.34M | $2.41M | $2.35M | $1.24M | $1.22M |
| **Total Liabilities** | $18.55M | $17.59M | $15.19M | $13.27M | $18.06M | $13.76M | $12.20M | $10.05M |
| **Total Debt (incl. Leases)** | $919K | $1.03M | $1.13M | $1.24M | $1.35M | $2.34M | $249K | $427K |
| Common Stock | $11K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $7.0K | $6.0K |
| Retained Earnings | -$517.7M | -$494.1M | -$469.5M | -$445.4M | -$421.5M | -$399.7M | -$377.7M | -$355.0M |
| Accumulated Other Comp. Income | $260K | $109K | -$22K | $51K | -$279K | $160K | -$443K | -$321K |
| **Total Stockholders' Equity** | $1.01B | $284.1M | $305.2M | $326.0M | $345.9M | $364.5M | $218.7M | $236.7M |
| Total Equity | $1.01B | $284.1M | $305.2M | $326.0M | $345.9M | $364.5M | $218.7M | $236.7M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$96.21M | -$88.85M | -$90.21M | -$60.34M | -$50.16M | -$40.57M |
| Depreciation & Amortization | $90K | $319K | $292K | $484K | $512K | $394K |
| Stock-Based Compensation | $13.40M | $15.63M | $25.54M | $10.77M | $8.15M | $1.69M |
| Change in Payables | -$512K | -$367K | $1.15M | -$722K | $1.73M | -$1.15M |
| **Operating Cash Flow** | -$82.18M | -$70.02M | -$67.39M | -$49.11M | -$41.83M | -$29.81M |
| Capital Expenditure | $0 | -$42K | -$52K | -$275K | -$340K | -$584K |
| **Free Cash Flow** | -$82.18M | -$70.06M | -$67.44M | -$49.38M | -$42.17M | -$30.39M |
| Purchases of Investments | -$405.0M | -$169.9M | -$275.8M | -$139.7M | -$166.3M | -$715K |
| **Investing Cash Flow** | -$298.0M | -$12.41M | -$37.99M | -$22.27M | -$119.7M | $6.69M |
| Common Stock Issued | $513K | $623K | $410K | $81.11M | $0 | -- |
| **Financing Cash Flow** | $743.5M | $164.0M | $41.95M | $167.1M | $134.4M | $85.52M |
| **Net Change in Cash** | $363.3M | $81.51M | -$63.31M | $95.54M | -$27.16M | $62.48M |

### Cash Flow Statement (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$23.57M | -$24.64M | -$24.09M | -$23.91M | -$21.80M | -$21.95M | -$22.74M | -$22.37M |
| Depreciation & Amortization | $12K | $12K | $11K | $55K | $66K | $83K | $88K | $82K |
| Stock-Based Compensation | $3.35M | $3.34M | $3.03M | $3.68M | $3.02M | $4.16M | $4.42M | $4.03M |
| Change in Payables | -$1.31M | $97K | $71K | $630K | $415K | -$140K | $172K | -$814K |
| **Operating Cash Flow** | -$19.08M | -$19.77M | -$18.88M | -$24.44M | -$14.58M | -$16.45M | -$16.18M | -$22.80M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $0 | -$13K | -$29K |
| **Free Cash Flow** | -$19.08M | -$19.77M | -$18.88M | -$24.44M | -$14.58M | -$16.45M | -$16.19M | -$22.83M |
| Purchases of Investments | -$380.0M | $0 | $0 | -$25.04M | -$119.3M | $0 | $0 | -$50.59M |
| **Investing Cash Flow** | -$350.0M | $24.50M | $25.50M | $1.96M | -$94.35M | $31.75M | $42.19M | $8.00M |
| **Financing Cash Flow** | $743.1M | $0 | $324K | $68K | $304K | $163.3M | $399K | $0 |
| **Net Change in Cash** | $374.0M | $4.73M | $6.94M | -$22.42M | -$108.7M | $178.6M | $26.40M | -$14.83M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -4986.0% | -- |
| **Net Profit Margin** | -- | -- | -- | -- | -5015.8% | -- |
| Return on Equity (ROE) | -9.6% | -25.7% | -35.3% | -21.8% | -31.3% | -- |
| Return on Assets (ROA) | -9.4% | -24.4% | -33.6% | -21.0% | -29.8% | -43.4% |
| Current Ratio | 62.41x | 23.14x | 22.39x | 33.68x | 24.48x | 3.98x |
| Quick Ratio | 62.09x | 22.89x | 22.06x | 33.43x | 24.34x | 3.28x |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | -- | -- |
| **Revenue Growth (YoY)** | -- | -- | -- | -100.0% | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -9.6% | -33.2% | -30.1% | -27.7% | -25.7% | -24.2% | -43.9% | -38.5% |
| Return on Assets (ROA) | -9.4% | -31.3% | -28.6% | -26.6% | -24.4% | -23.3% | -41.5% | -36.9% |
| Current Ratio | 62.41x | 19.52x | 24.70x | 30.89x | 23.14x | 32.99x | 21.02x | 27.85x |
| Quick Ratio | 62.09x | 19.21x | 24.43x | 30.57x | 22.89x | 32.67x | 20.57x | 27.26x |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
